Page last updated: 2024-11-04

glycerate 1,3-biphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3-phospho-D-glyceroyl dihydrogen phosphate : The (R)-enantiomer of 3-phosphoglyceroyl dihydrogen phosphate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439191
CHEBI ID16001
SCHEMBL ID4360927
MeSH IDM0065509

Synonyms (32)

Synonym
x15 ,
1,3-bisphosphoglyceric acid
(2r)-2-hydroxy-1-oxopropane-1,3-diyl bis(dihydrogen phosphate)
CHEBI:16001
3-phospho-d-glyceroyl dihydrogen phosphate
3-phospho-d-glyceroyl phosphate
1,3-bisphospho-d-glycerate
(r)-2-hydroxy-3-(phosphonooxy)-1-monoanhydride with phosphoric propanoic acid
38168-82-0
C00236
d-glycerate 1,3-diphosphate
1,3-diphosphoglycerate
phosphono (2r)-2-hydroxy-3-phosphonooxypropanoate
SCHEMBL4360927
1,3-biphosphoglycerate
glycerate 1,3-biphosphate
1,3-biphosphoglyceric acid
1,3-bisphosphoglycerate
13-dpg
2-hydroxy-3-(phosphonooxy)-propanoate
1,3-bis-phosphoglycerate
2-hydroxy-3-(phosphonooxy)-propanoic acid
1,3-diphosphateglycerate
glycerate 1,3-diphosphate
2-hydroxy-3-(phosphonooxy)-propanoic acid 1-anhydride with phosphoric acid
2-hydroxy-3-(phosphonooxy)-propanoic acid 1-anhydride with phosphorate
3-phospho-d-glyceroyl-phosphate
3-phosphoglyceroyl-phosphate
(2r)-2-hydroxy-1-oxopropane-1,3-diyl bis[dihydrogen (phosphate)]
Q27098334
1,3-bisphospho-d-glyceric acid
DTXSID101305707
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
acyl monophosphateAn organic phosphate ester or anhydride formed by condensation of phosphoric acid with a carboxylic acid.
2,3-bisphosphoglyceric acidA bisphosphoglyceric acid that is glyceric acid carrying two phospho substituents at positions 2 and 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (20)

PathwayProteinsCompounds
Glycolysis and Gluconeogenesis ( Glycolysis and Gluconeogenesis )2718
NADH + 1,3-Bisphospho-D-glyceric acid = NAD+ + D-Glyceraldehyde 3-phosphate + Orthophosphate ( Glycolysis and Gluconeogenesis )25
ATP + D-Glycerate 3-phosphate = ADP + 1,3-Bisphospho-D-glyceric acid ( Glycolysis and Gluconeogenesis )24
Aerobic glycolysis020
Metabolic Epileptic Disorders2589
superpathway of central carbon metabolism346
glycolysis I118
superpathway of glycolysis, pyruvate dehydrogenase and TCA cycle134
sucrose degradation to ethanol and lactate (anaerobic)028
superpathway of glycolysis and Entner-Doudoroff023
glycolysis II017
glycolysis III018
Relationship between glutathione and NADPH036
Hexoses metabolism in proximal tubules016
Gluconeogenesis012
Primary carbon metabolism2330
Glycolysis and Gluconeogenesis08
Metabolism overview078
Biochemical pathways: part I0466
Metabolic reprogramming in colon cancer029
Glycolysis and gluconeogenesis017

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (23.44)18.7374
1990's18 (28.13)18.2507
2000's17 (26.56)29.6817
2010's11 (17.19)24.3611
2020's3 (4.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]